Efficacy study of PD-1 or PD-L1 inhibitors in pulmonary pleomorphic carcinoma patients
Latest Information Update: 13 May 2020
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 13 May 2020 New trial record
- 01 May 2020 Results published in the European Journal of Cancer